Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group.
Graham BS, McElrath MJ, Connor RI, Schwartz DH, Gorse GJ, Keefer MC, Mulligan MJ, Matthews TJ, Wolinsky SM, Montefiori DC, Vermund SH, Lambert JS, Corey L, Belshe RB, Dolin R, Wright PF, Korber BT, Wolff MC, Fast PE. Graham BS, et al. Among authors: lambert js. J Infect Dis. 1998 Feb;177(2):310-9. doi: 10.1086/514209. J Infect Dis. 1998. PMID: 9466516 Clinical Trial.
Antibody to human immunodeficiency virus type 1 (HIV-1) gp160 in mucosal specimens of asymptomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 IIIB gp160 vaccine. The National Institute of Allergy and Infectious Diseases-sponsored AIDS Vaccine Evaluation Group.
Lambert JS, Viscidi R, Walker MC, Clayman B, Winget M, Wolff M, Schwartz DH. Lambert JS, et al. Clin Diagn Lab Immunol. 1997 May;4(3):302-8. doi: 10.1128/cdli.4.3.302-308.1997. Clin Diagn Lab Immunol. 1997. PMID: 9144368 Free PMC article. Clinical Trial.
Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults.
King JC Jr, Treanor J, Fast PE, Wolff M, Yan L, Iacuzio D, Readmond B, O'Brien D, Mallon K, Highsmith WE, Lambert JS, Belshe RB. King JC Jr, et al. Among authors: lambert js. J Infect Dis. 2000 Feb;181(2):725-8. doi: 10.1086/315246. J Infect Dis. 2000. PMID: 10669363 Clinical Trial.
Safety and immunogenicity of HIV recombinant envelope vaccines in HIV-infected infants and children. National Institutes of Health-sponsored Pediatric AIDS Clinical Trials Group (ACTG-218).
Lambert JS, McNamara J, Katz SL, Fenton T, Kang M, VanCott TC, Livingston R, Hawkins E, Moye J Jr, Borkowsky W, Johnson D, Yogev R, Duliege AM, Francis D, Gershon A, Wara D, Martin N, Levin M, McSherry G, Smith G. Lambert JS, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 15;19(5):451-61. doi: 10.1097/00042560-199812150-00003. J Acquir Immune Defic Syndr Hum Retrovirol. 1998. PMID: 9859958 Clinical Trial.
HIV vaccines in infants and children.
Lambert JS. Lambert JS. Paediatr Drugs. 2005;7(5):267-76. doi: 10.2165/00148581-200507050-00001. Paediatr Drugs. 2005. PMID: 16220994 Review.
Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group.
Lambert JS, Mofenson LM, Fletcher CV, Moye J Jr, Stiehm ER, Meyer WA 3rd, Nemo GJ, Mathieson BJ, Hirsch G, Sapan CV, Cummins LM, Jimenez E, O'Neill E, Kovacs A, Stek A. Lambert JS, et al. J Infect Dis. 1997 Feb;175(2):283-91. doi: 10.1093/infdis/175.2.283. J Infect Dis. 1997. PMID: 9203648 Clinical Trial.
Pediatric HIV infection.
Lambert JS. Lambert JS. Curr Opin Pediatr. 1996 Dec;8(6):606-14. doi: 10.1097/00008480-199612000-00011. Curr Opin Pediatr. 1996. PMID: 9018445 Review.
167 results